Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why

Dermata Therapeutics Inc DRMA announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic skin conditions. DMT410 showed improvements in pore size, luminosity, brightness, and overall aesthetic appearance.

• The duration of the treatment effect lasted approximately three months.
• The Company did say that upper facial lines, a measurement of the visible improvement of a patient's forehead, lateral canthal, and glabellar lines, did not show clinically meaningful improvement.
• Dermata said that minimal effect on the upper facial lines was expected as it did not expect OnabotuliniumtoxinA to penetrate the muscle.
• DMT410 was generally safe and well-tolerated with no adverse events reported, no withdrawals due to treatment-related adverse events, and no potential distant spread of toxin reported.
• Related Link: Why Are Dermata Therapeutics Shares Trading Higher Today?
• Price Action: DRMA shares are down 29.4% at $3.35 during the market session on the last check Friday.